Key facts
- This page summarizes Patrick J. Heron's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Jun 2024, 18:22.
Patrick J. Heron - 05 Jun 2024 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)
- Reporting relationship
- Director
- Issuer ticker
- MIRM
- Reported as of
- 05 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2024, 18:22:06 UTC
- Prior SEC filing
- 06 Mar 2024
- Next SEC filing
- 30 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Judit Ryvkin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick J. Heron filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 07 Jun 2024.
Change
- Previous filing in this sequence was filed on 06 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRM
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +8,779
- Change %
- Price
- $0.000000
- Shares after
- 8,779
- Date
- 05 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,779
- Exercise price
- $26.30
- Footnotes
- F1
MIRM
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +5,703
- Change %
- Price
- $0.000000
- Shares after
- 5,703
- Date
- 05 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,703
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2025 annual stockholder meeting.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting.